Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
NCT07235917Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Functional hypothalamic amenorrhea (FHA) comparing Mibavademab with Placebo (2 arms). Primary endpoint: Change from the highest serum estradiol observed during a 28-day period. Started Mar 2026; status: recruiting.
02
Drugs
mibavademab
03
Conditions
Functional hypothalamic amenorrhea (FHA)
Beyond the preview
Go deeper on NCT07235917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07235917.